Navegando por Assunto "Paclitaxel"
Agora exibindo 1 - 2 de 2
- Resultados por página
- Opções de Ordenação
Item Acesso aberto (Open Access) Avaliação do uso de nanopartículas lipídicas que se ligam a receptores celulares como instrumento para a terapêutica do câncer(Universidade Federal do Pará, 2014-12-19) FEIO, Danielle Cristinne Azevedo; LIMA, Patrícia Danielle Lima de; http://lattes.cnpq.br/3411620003450812Lipid-based nanoparticle systems have been used as vehicles for chemotherapeutic agents in experimental cancer treatments. More recently, those preparations have also been assayed in animal models of cardiovascular, rheumatic and other chronic inflammatory diseases. In general those systems reportedly attenuate the severe toxicities of chemotherapeutic agents. This study was aimed to investigate the effects of associating paclitaxel to a lipid-based nanoparticle system upon the organism of a non-human primate, Cebus apella, by extensively documenting the toxicity by serum biochemistry, hematological and detailed histopathological methods. The lipid nanoparticles (LDE) were constituted of cholesterol esters and esterified cholesterol, lecithin and triolin, with addition of paclitaxel. Eighteen Cebus apella were studied; three animals were treated with LDE only, without paclitaxel, as ministered intravenously every three weeks, during six treatment cycles; six animals were treated with paclitaxel associated to LDE at the same administration scheme, three with the lower (175mg/m2) and three with higher (250mg/m2) paclitaxel doses; six animals were treated with commercial paclitaxel, three with the lower and three with the higher doses levels. Three weeks after the treatment cycle the animals were euthanized by lethal anesthetic dose, and tissues fragments were collected for histopathological analysis. In three non-treated animals, the plasma kinetics of LDE’s labeled with radioactive cholesterol was determined after intravenous injection and blood sampling over 24 hours. The ethics committee in research with experimental animals UFPA (BIO008-11) approved the project. In the LDE-paclitaxel group, no clinical toxicity appeared, and the weight food consumption curve were similar to controls. Treatment was interrupted after the second cycle in four animals of commercial paclitaxel group for very high clinical toxicity but the remaining two complete the 6-cycle-treatment. Those two animals presented weight loss, nausea and vomiting, diarrhea, escame decamation, 70% fur loss and loss of physical activity. The 175mg/m2 paclitaxel dose is used in cancer chemoterapie with considerable toxicity, while the 250 mg/m2 dose shows intorable toxicity to the patients. The use of LDE as carrier in both those levels was almost complete neutralized the toxicity of the drug in this species more closed related to human subjects. This was observed not only by clinical, biochemical and hematological profiles but also by the histopathological analysis of stomach, small and large intestine, esophagus, pancreas, trachea and gallbladder. The current results support the assumption that lipid-based nanoparticles systems used was drug carriers can offer valuable tools decrease the toxicity and increase the safety of the chemotherapeutic agents, while extending the use to chronic diseases other than cancer.Item Acesso aberto (Open Access) Avaliação seriada do perfil hematológico e bioquímico de primatas não humanos da espécie Sapajus apella tratados com lde-oleato de paclitaxel como instrumento para a terapêutica do câncer(Universidade Federal do Pará, 2017-02-23) OLIVEIRA, Nayara Cristina Lima de; BURBANO, Rommel Mario Rodriguéz; http://lattes.cnpq.br/4362051219348099Study of a chemotherapy delivery system, called LDE, with lipid composition similar to the natural low density lipoproteins of the body, denominated by the acronym LDL. LDEs have advantages over commercial chemical forms, since it is able to concentrate in the neoplastic tissues after injection into the circulatory chain, thus being able to target the tumors. LDE can be used as a "carrier" of paclitaxel (PTX) for possible reduction of toxicity and increase of its therapeutic action. The use of non-human primates as in vivo experimental models are of great importance in human health applications due to their anatomical, biochemical and phylogenetic similarities with human primates, generating results that can be interpreted more closely and safely to The phenomena in humans. The aim of the project was to evaluate the chronic toxicity of nanoparticles associated with to chemotherapy Paclitaxel (LDE-PTX) in individuals of the Sapajus apella species, based on the determination of hematological and biochemical parameters and their possible alterations. During the research 15 animals were used, divided into groups: Negative control (CN); Experimental (EXP1 and EXP2) where the animals received LDE-PTX intravenously two different doses of 175 mg / m2 and 250 mg / m2 respectively; and positive control (CP1 and CP2) where the animals intravenously received the drug in commercial form at the same doses used in the experimental group, respectively. Primates were accompanied for 6 cycles of chemotherapy, with interval of 3 weeks. Hematological and biochemical analysis was performed at each cycle through erythrogram and leukogram, alkaline phosphatase, total protein, albumin and globulin, total bilirubin and fractions, glycemia, amylase and serum lipase. E of the sodium and potassium eletrolytes were carried out in the serum of the animals during the collection days. Data were expressed as mean ± standard deviation and submitted to analysis of variance ANOVA, with Bonferroni post-test with significance for p <0.05, through BioEstat®5.3. The obtained results demonstrated advantages of the use of LDE-PTX, since the hematological tests demonstrate that there was a lower toxicity in all the chemotherapeutic cycles and the non-alteration of the majority of the biochemical parameters, demonstrate that the toxicity of the tested drug associated to LDE present smaller Effect toxic than its commercial version. It was concluded from the analysis of the results that hematological and biochemical toxicity was lower in treatment with PTX associated with LDE than treatment of PTX in its commercial form.